Over the past 2 decades, combination antiretroviral therapy (ART) has been a cornerstone of the response to the epidemic of human immunodeficiency virus (HIV) infection that causes AIDS \[[@CIT0001]\]. The scale-up of ART has resulted in substantial reductions in AIDS-related mortality and morbidity, as well as reduced HIV transmission \[[@CIT0004]\]. Nevertheless, less than half of the estimated 36.7 million people living with HIV (PLWH) were receiving ART in 2015 \[[@CIT0009]\].

Historically, there has been an early consensus that PLWH who had an AIDS-defining illness should initiate ART immediately. For those who had not yet progressed to AIDS, the World Health Organization (WHO) has recommended that CD4^+^ T-lymphocyte thresholds guide the timing of ART initiation \[[@CIT0010]\]. However, observational studies, predominantly carried out in resource-rich settings \[[@CIT0011]\], have found that ART initiation among PLWH with CD4 counts \>500 cells/μL was associated with substantial clinical benefits, and this has now been confirmed by prospective randomized trials \[[@CIT0012]\]. Taken together with the results of the HPTN 052 trial \[[@CIT0007], [@CIT0008]\], showing the sustained ability of ART to prevent sexual transmission of HIV, these findings led the WHO to revise their recommendation in September 2015, now completely removing the CD4 count threshold, such that ART is globally recommended for all PLWH \[[@CIT0016]\].

Standard of care for all those diagnosed with HIV infection in China includes free CD4 testing each year, with the first CD4 test offered soon after diagnosis. From 2008 to 2014, the primary criterion for entry into the Chinese National Free Antiretroviral Treatment Program (NFATP) was CD4 count ≤350 cells/μL. During this time, exceptions to the CD4 threshold of ≤350 cells/μL in the NFATP included patients with coinfections, and prevention of mother-to-child transmission \[[@CIT0017]\]. In 2011, the NFATP added a recommendation that ART be offered to all PLWH in serodiscordant relationships, regardless of CD4 cell count \[[@CIT0017]\]. In 2012, a special national project for the "Prevention and Treatment of Major Infectious Diseases" was launched, wherein the National Center for AIDS/STD Control and Prevention (NCAIDS) of the Chinese Center for Disease Control and Prevention (China CDC) implemented a series of cluster-randomized trials among key populations, including men who have sex with men, serodiscordant couples, people who inject drugs, and commercial sex workers. The targeted outcome was early identification of HIV infection and immediate ART initiation regardless of CD4 cell count. Thus, PLWH participating in the study were exempt from the standard-of-care CD4 threshold for ART initiation.

The primary aim of the present study was to examine mortality and its determinants among a cohort of newly diagnosed PLWH with first CD4 count \>500 cells/μL. Participants were followed for 1 year to examine the impact of immediate ART initiation on mortality among PLWH with high CD4 counts, compared to those with delayed ART initiation and to those who remained ART naive. Secondarily, we also sought to describe causes of death within our cohort.

METHODS {#s5}
=======

Study Design and Setting {#s6}
------------------------

This nationwide, observational cohort study was designed to examine mortality among patients who received confirmed diagnoses of HIV infection between 1 January 2012 and 30 June 2014 and had a CD4 count \>500 cells/μL. Mortality and factors associated with mortality were assessed at 1 year. A flow diagram illustrating the study design is shown in [Figure 1](#F1){ref-type="fig"}. The treatment setting was China's NFATP. This program, as well as treatment regimens (eg, drug combinations used, dosage, and administration) and follow-up protocols for enrolled patients, have been described previously \[[@CIT0017], [@CIT0018]\].

![Flow diagram depicting study design and development of the cohort. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.](cix87801){#F1}

Data Source {#s7}
-----------

Data were extracted from China's Web-based national database for real-time collection and maintenance of information related to the HIV epidemic. This system, called the HIV/AIDS Comprehensive Response Information Management System (CRIMS), has been described elsewhere \[[@CIT0019]\]. Because screening for inclusion was nationwide and included all identified cases, sample size was not initially defined.

Data Collection and Inclusion Criteria {#s8}
--------------------------------------

All CRIMS records of persons with a confirmed diagnosis of HIV infection between 1 January 2012 and 30 June 2014 were extracted and then further screened for study eligibility criteria. In addition to a confirmed new HIV diagnosis, PLWH were included if they were 18 years or older at the time of diagnosis, had a CD4 test result within 1 year of diagnosis, had baseline (pre-ART) CD4 count of \>500 cells/μL, and had reported having acquired HIV through heterosexual contact, male-to-male sexual contact, or injection drug use. These transmission routes accounted for \>90% of newly diagnosed HIV infections in China during this time period \[[@CIT0022]\].

All eligible records were extracted and de-identified. Each study participant was followed from the date of their first CD4 test for 12 months afterward or the date of death, whichever came first. As illustrated in [Figure 1](#F1){ref-type="fig"}, participants were stratified by timing of ART initiation relative to the date of confirmed HIV diagnosis (≤30 days after HIV diagnosis referred to as the immediate ART group; \>30 days after HIV diagnosis referred to as the delayed ART group; and PLWH who did not start ART within 1 year referred to as the no ART group).

Mortality and Causes of Death {#s9}
-----------------------------

The main outcome measure was all-cause mortality. Dates and causes of death were obtained from clinical records. AIDS-related causes of death were defined by China CDC medical guidelines \[[@CIT0023]\]. Non-AIDS-related causes of death included all other causes.

Statistical Analysis {#s10}
--------------------

Continuous variables are presented using median and interquartile range (IQR), and categorical variables are presented using number and percentage. Because of the very large number of patients in our cohort, even very small differences between subgroups would likely result in *P* values reaching statistical significance. However, these small differences would not necessarily be meaningful. Therefore, we focused only on differences of ≥5% between groups being compared.

Observed time, in person-years (PY), was calculated for participants who contributed to the study observation. As the median time interval between confirmed HIV diagnosis and first CD4 test was only 14 days (IQR, 3--57 days), CD4 test date was selected as the start of observed time. Thus, observed time was calculated as the difference between the date of first CD4 test and the date of death or the end of the follow-up period, whichever came first. Mortality rate was calculated as the sum of deaths divided by the sum of observed time in PY. Due to survival bias, patients who accepted ART were always alive before ART initiation. Thus, ART status was treated as a time-dependent variable, meaning that those who accepted ART were a part of the no ART group until ART initiation. Individuals contributed person-time (and deaths) to the immediate ART group after they began ART, provided ART initiation occurred within 30 days of the start. Individuals contributed person-time to the delayed ART group after they began ART, provided ART initiation occurred after 30 days from the start but before 1 year. A multivariate Cox proportional hazards regression model was constructed to assess hazard ratios (HRs) for the study variable ART status, and for demographic variables and HIV clinical variables. The immediate ART variable in the regression model was considered time dependent. That is, it was set to 0 before ART initiation, and to 1 after ART initiation, provided it occurred before the end of day 30. Similarly, the delayed ART variable was set to 0 before ART initiation, and to 1 after ART initiation, provided it occurred after day 30, but within 1 year. Adjusted HRs for the study variable were generated to identify prognostic risk of death by controlling potential confounding bias caused by demographic variables and HIV clinical variables.

All *P* values presented are 2-sided, and *P* \< .05 was considered statistically significant. All analyses were performed using SAS software version 9.1.3 (SAS Institute).

Ethical Considerations {#s11}
----------------------

The study protocol was reviewed and approved by the Institutional Review Board of NCAIDS, China CDC. As patients entering CRIMS sign informed consent at time of enrollment, no further informed consent was required for this study. All patient records were de-identified prior to data analysis.

RESULTS {#s12}
=======

A full 212402 individual records with a date of confirmed HIV diagnosis between 1 January 2012 and 30 June 2014 were available for the study. A total of 34581 individuals (16.3%) met the eligibility criteria and were included in the final study cohort. Development of the cohort is illustrated in [Figure 1](#F1){ref-type="fig"}.

Characteristics of the Cohort {#s13}
-----------------------------

Characteristics of the entire study cohort, as well as individual subgroups thereof, are shown in [Table 1](#T1){ref-type="table"}. The median age of patients in the cohort was 32 years (IQR, 25--42 years). A majority were male (75.0%), Han Chinese (72.2%), had junior middle school education or less (63.7%), were single, divorced, or widowed (60.8%), and self-reported acquisition of HIV infection via heterosexual contact (59.9%). Median baseline CD4 count was 616 cells/μL (IQR, 549--732 cells/μL).

###### 

Baseline Characteristics of the Entire Study Cohort and of Each Subgroup Based on Antiretroviral Therapy Timing After Confirmed Human Immunodeficiency Virus Diagnosis

  Characteristics                      Entire Study Cohort   ART Timing After Confirmed HIV Diagnosis                    
  ------------------------------------ --------------------- ------------------------------------------ ---------------- ----------------
  Total                                34581 (100.0)         1838 (100.0)                               5640 (100.0)     27103 (100.0)
  Age, y                                                                                                                 
   Median (IQR)                        32 (25--42)           34 (27--46)                                33 (26--45)      31 (25--41)
   18--29                              14771 (42.7)          653 (35.5)                                 2110 (37.4)      12008 (44.3)
   30--49                              14976 (43.3)          816 (44.4)                                 2565 (45.5)      11595 (42.8)
   ≥50                                 4834 (14.0)           369 (20.1)                                 965 (17.1)       3500 (12.9)
  Sex                                                                                                                    
   Male                                25927 (75.0)          1160 (63.1)                                4058 (72.0)      20709 (76.4)
   Female                              8654 (25.0)           678 (36.9)                                 1582 (28.1)      6394 (23.6)
  Ethnicity                                                                                                              
   Han                                 24969 (72.2)          1176 (64.0)                                4029 (71.4)      19764 (72.9)
   Other                               9612 (27.8)           662 (36.0)                                 1611 (28.6)      7339 (27.1)
  Education level                                                                                                        
   Junior middle school or less        22039 (63.7)          1323 (72.0)                                3630 (64.4)      17086 (63.0)
   Senior middle school or higher      12542 (36.3)          515 (28.0)                                 2010 (35.6)      10017 (37.0)
  Marital status                                                                                                         
   Single, divorced, or widowed        21019 (60.8)          783 (42.6)                                 2829 (50.2)      17407 (64.2)
   Married or cohabiting               13562 (39.2)          1055 (57.4)                                2811 (49.8)      9696 (35.8)
  Transmission route                                                                                                     
   Heterosexual contact                20713 (59.9)          1409 (76.7)                                3615 (64.1)      15689 (57.9)
   Male-to-male sexual contact         10167 (29.4)          348 (18.9)                                 1674 (29.7)      8145 (30.1)
   Injecting drug use                  3701 (10.7)           81 (4.4)                                   351 (6.2)        3269 (12.1)
  Baseline CD4 count, cells/μL                                                                                           
   Median (IQR)                        616 (549--732)        596 (538--694)                             594 (540--692)   623 (552--744)
  Time from diagnosis to CD4 test, d                                                                                     
   Median (IQR)                        14 (3--57)            6 (0--20)                                  11 (1--39)       18 (4--65)
  Time from CD4 to ART, d                                                                                                
   Median (IQR)                                              10 (4--18)                                 197 (109--283)   

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; IQR, interquartile range.

Characteristics of Groups Stratified by Timing of ART Initiation {#s14}
----------------------------------------------------------------

Among 34581 PLWH, 1838 (5.3%) initiated ART within 30 days of diagnosis and were included in the immediate ART group and 5640 (16.3%) initiated ART \>30 days after diagnosis and were included in the delayed ART group. The remaining 27103 PLWH (78.4%) formed the no ART group. A larger proportion of PLWH in the immediate ART group were female (36.9% vs 28.1% for the delayed ART group and 23.6% for the no-ART group), ethnic minorities (36.0% vs 28.6% and 27.1%), less well educated (junior middle school or less: 72.0% vs 64.4% and 63.0%), married or cohabitating (57.4% vs 49.8% and 35.8%), and reported heterosexual contact as their mode of HIV acquisition (76.7% vs 64.1% and 57.9%).

Mortality and Causes of Death {#s15}
-----------------------------

Deaths and mortality rates are shown in [Table 2](#T2){ref-type="table"}. The 34581 PLWH in the study cohort were followed from the date of their first CD4 test until 1 year after or death, whichever was first, resulting in a total observed time of 34188 PY. Seven hundred ninety deaths of 34581 (2.3%) were documented, for an overall mortality rate of 2.31 per 100 PY.

###### 

Cox Proportional Hazards Regression Models for Mortality Rates and Associated Risk Factors

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                    Entire Study Cohort, No. (%)   Deaths,\      Observed Time ^a^ , PY   Mortality\        Unadjusted\          *P* Value   Adjusted\           *P* Value
                                                                   No. (%)                                Rate per 100 PY   HR (95% CI)                      HR (95% CI)         
  --------------------------------- ------------------------------ ------------- ------------------------ ----------------- -------------------- ----------- ------------------- -----------
  Total                             34581 (100.0)                  790 (100.0)   34188                    2.31                                                                   

  Age, y                                                                                                                                                                         

   18--29                           14771 (42.7)                   122 (15.4)    14718                    0.83              1.00                             1.00                

   30--49                           14976 (43.3)                   334 (42.3)    14809                    2.26              2.72 (2.21--3.35)    \<.001      2.03 (1.64--2.52)   \<.001

   ≥50                              4834 (14.0)                    334 (42.3)    4661                     7.17              8.65 (7.03--10.64)   \<.001      6.10 (4.87--7.64)   \<.001

  Sex                                                                                                                                                                            

   Male                             25927 (75.0)                   629 (79.6)    25616                    2.46              1.31 (1.10--1.56)    .002        1.90 (1.59--2.27)   \<.001

   Female                           8654 (25.0)                    161 (20.4)    8573                     1.88              1.00                             1.00                

  Ethnicity                                                                                                                                                                      

   Han                              24969 (72.2)                   543 (68.7)    24692                    2.20              1.00                             1.00                

   Other                            9612 (27.8)                    247 (31.3)    9497                     2.60              1.18 (1.02--1.38)    .03         1.09 (.93--1.28)    .30

  Education level                                                                                                                                                                

   Junior middle school or less     22039 (63.7)                   688 (87.1)    21691                    3.17              3.89 (3.16--4.78)    \<.001      1.85 (1.48--2.31)   \<.001

   Senior middle school or higher   12542 (36.3)                   102 (12.9)    12498                    0.82              1.00                             1.00                

  Marital status                                                                                                                                                                 

   Single, divorced, or widowed     21019 (60.8)                   411 (52.0)    20814                    1.97              1.00                             1.00                

   Married or cohabitating          13562 (39.2)                   379 (48.0)    13375                    2.83              1.44 (1.25--1.65)    \<.001      0.88 (.76--1.02)    .928

  Transmission route                                                                                                                                                             

   Heterosexual contact             20713 (59.9)                   623 (78.9)    20394                    3.05              7.04 (5.19--9.56)    \<.001      4.16 (2.99--5.77)   \<.001

   Male-to-male sexual contact      10167 (29.4)                   44 (5.6)      10145                    0.43              1.00                             1.00                

   Injection drug use               3701 (10.7)                    123 (15.6)    3649                     3.37              7.77 (5.51--10.97)   \<.001      5.07 (3.49--7.35)   \<.001

  ART status^b^                                                                                                                                                                  

   Immediate ART                    1838 (5.3)                     19 (2.4)      1828                     1.04              0.44 (.28--.69)      \<.001      0.37 (.23--.58)     \<.001

   Delayed ART                      5640 (16.3)                    58 (7.3)      2583                     2.25              0.80 (.61--1.05)     .11         0.74 (.57--.98)     .04

   No ART                           27103 (78.4)                   713 (90.3)    29778                    2.39              1.00                             1.00                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; PY, person-years.

^a^Observed time, in PY, was calculated as beginning on the date of first CD4 test, and ending at 1 year or on the date of death, whichever came first.

^b^ART was treated as the time-dependent variable; immediate ART means ART was initiated within 30 days of confirmed human immunodeficiency virus (HIV) diagnosis; delayed ART means ART was initiated \>30 days after diagnosis, but within 1 year; no ART means that ART was never initiated in the 1 year after HIV diagnosis.

Among the 1838 PLWH in the immediate ART group, 19 deaths were observed within 1828 PY of observed time, for a mortality rate of 1.04 per 100 PY. Fifty-eight deaths were documented among the 5640 PLWH in the delayed ART group within 2583 PY of observed time, for a mortality rate of 2.25 per 100 PY. Finally, 713 deaths were documented among the 27103 PLWH in the no ART group within 29778 PY of observed time, for a mortality rate of 2.39 per 100 PY.

The causes of death are presented in [Table 3](#T3){ref-type="table"}. Causes of death for a majority of the 790 PLWH were documented as non-AIDS-related complications (76.3%). A further 8.6% of PLWH had no cause of death documented or an unclassified cause of death listed in their record. AIDS-related complications were identified as the cause of death for 15.1%. In the immediate ART group, no AIDS-related causes of death were documented. The most common non-AIDS cause was cardiovascular disease (36.8%). Among those in the delayed ART group, 41.4% died from AIDS-related causes, whereas 55.1% died from non-AIDS-related causes. In the no ART group, a majority of deaths were documented as having non-AIDS-related causes (77.6%), the most frequent of which were other diseases (13.9%), respiratory disease (13.1%), and non-disease-related deaths/accidents (12.9%).

###### 

Causes of Death During Follow-up

  Cause of Death                        Entire Study Cohort   ART Timing After Confirmed HIV Diagnosis                
  ------------------------------------- --------------------- ------------------------------------------ ------------ -------------
  Total                                 790 (100.0)           19 (100.0)                                 58 (100.0)   713 (100.0)
  AIDS-related                          119 (15.1)            0 (0.0)                                    24 (41.4)    95 (13.3)
   AIDS-defining cancer                 10 (1.3)                                                         1 (1.7)      9 (1.3)
   CNS infection                        3 (0.4)                                                          1 (1.7)      2 (0.3)
   Tuberculosis                         15 (1.9)                                                         2 (3.5)      13 (1.8)
   Cryptococcal meningitis              4 (0.5)                                                          1 (1.7)      3 (0.4)
   Herpes virus infection               4 (0.5)                                                                       4 (0.6)
   Wasting syndrome                     6 (0.8)                                                          2 (3.5)      4 (0.6)
   Candidiasis                          5 (0.6)                                                          2 (3.5)      3 (0.4)
   Recurrent pneumonia                  5 (0.6)                                                          1 (1.7)      4 (0.6)
   Pneumocystis pneumonia               14 (1.8)                                                         3 (5.2)      11 (1.5)
   Cryptosporidiosis                    2 (0.3)                                                          1 (1.7)      1 (0.1)
   Other infections                     12 (1.5)                                                                      12 (1.6)
   Other                                39 (4.9)                                                         10 (17.2)    29 (4.1)
  Non-AIDS-related                      603 (76.3)            18 (94.7)                                  32 (55.1)    553 (77.6)
   Non-AIDS-defining cancer             80 (10.1)                                                        4 (6.9)      76 (10.7)
   Cardiovascular disease               94 (11.9)             7 (36.8)                                   6 (10.3)     81 (11.4)
   Overdose of illicit drugs            45 (5.7)              1 (5.3)                                    1 (1.7)      43 (6.0)
   Suicide                              35 (4.4)              2 (10.5)                                   2 (3.5)      31 (4.3)
   Hepatitis B or C virus               12 (1.5)              1 (5.3)                                    1 (1.7)      10 (1.4)
   Respiratory disease                  98 (12.4)             3 (15.8)                                   2 (3.5)      93 (13.1)
   Metabolic disease                    10 (1.3)              2 (10.5)                                   2 (3.5)      6 (0.8)
   Gastrointestinal disease             22 (2.8)                                                         1 (1.7)      21 (3.0)
   Medicine-related events              1 (0.1)                                                                       1 (0.1)
   Other diseases                       107 (13.6)            2 (10.5)                                   6 (10.3)     99 (13.9)
   Non-disease-related death/accident   99 (12.5)                                                        7 (12.0)     92 (12.9)
  Unknown                               68 (8.6)              1 (5.3)                                    2 (3.5)      65 (9.1)
   Unclassified                         66 (8.3)              1 (5.3)                                    2 (3.5)      63 (8.8)
   Missing                              2 (0.3)               0 (0.0)                                    0 (0.0)      2 (0.3)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: ART, antiretroviral therapy; CNS, central nervous system; HIV, human immunodeficiency virus.

Factors Associated With Death {#s16}
-----------------------------

Factors associated with death within 1 year are presented in [Table 2](#T2){ref-type="table"}. Higher risk of death was associated with older age (30--49 years: adjusted HR, 2.03, *P* \< .001; ≥50 years: adjusted HR, 6.10, *P* \< .001), being male (adjusted HR, 1.90, *P* \< .001), having only a junior middle school education or less (adjusted HR, 1.85, *P* \< .001), and having been infected via heterosexual contact (adjusted HR, 4.16, *P* \< .001) or injection drug use (adjusted HR, 5.07, *P* \< .001). As far as the timing of ART initiation, immediate ART (initiating within 30 days of diagnosis) provided the strongest protection against death (adjusted HR, 0.37, *P* \< .001), while delayed ART (initiating after 30 days of diagnosis, but within 1 year) provided more modest protection (adjusted HR, 0.74, *P* = .040) relative to not receiving ART within the first year.

DISCUSSION {#s17}
==========

Our results demonstrate that PLWH with a CD4 count \>500 cells/μL who initiated ART within 30 days of diagnosis (immediate ART group) experienced a 63% decrease in mortality. Additional risk factors for mortality in this study were older age, being male, having a lesser education, and becoming infected via injection drug use or heterosexual contact. A majority of deaths observed were attributed to non-AIDS-related complications. Our results confirm those from the recent START (strategic timing of antiretroviral treatment) and TEMPRANO (early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults -- ANRS 12136 TEMPRANO) studies \[[@CIT0012], [@CIT0015]\], and further indicate that these results are also generalizable to China.

The push for earlier ART initiation has recently been formalized through policy recommendations \[[@CIT0016]\]. Arguments to delay ART initiation based on the use of a CD4 cell count threshold include concerns about drug resistance, side effects, resource allocation, and adherence \[[@CIT0024]\]. However, research studies have definitively concluded that the potential clinical and public health benefits of immediate ART initiation far outweigh the risks. Our results highlight the urgency of immediate ART initiation among PLWH with high CD4 cell counts.

HIV-infected, ART-naive patients with high CD4 cell counts still experience elevated mortality compared with the general population \[[@CIT0030], [@CIT0031]\]. Non-AIDS events remain common among this group \[[@CIT0032], [@CIT0033]\], and non-AIDS-related mortality can exceed AIDS-related mortality \[[@CIT0034]\]. In settings outside of China, a high proportion of non-AIDS mortality has been attributed to illicit drug use, suicide, unintentional injury, and violence \[[@CIT0035], [@CIT0036]\]. A cohort study of ART-naive PLWH with CD4 count \>350 cells/μL in Europe and North America found that only 14.6% of deaths were categorized as AIDS-related, whereas 44.9% were categorized as non-AIDS-related (40.6% of deaths in the study were due to unknown causes) \[[@CIT0030]\]. In our study, 94.7% of deaths in the immediate ART group, 55.1% in the delayed ART group, and 77.6% in the no ART group were classified as non-AIDS-related deaths \[[@CIT0034]\]. Consistent with other studies, the most common causes of death observed were cardiovascular disease, liver disease, non-AIDS-defining malignancies, overdose, suicide, and accidental deaths \[[@CIT0033], [@CIT0035]\].

In addition to the direct benefit of ART for survival, it is also likely that regular follow-up and comprehensive care services associated with ART use contributed to the decreased mortality observed. After ART initiation, patients entered into the stable care system and received multidisciplinary services including regular medical visits as well as psychosocial support \[[@CIT0039], [@CIT0040]\]. ART clinics provided chronic disease management and cancer and cardiovascular disease screening, which may have contributed to the improvement in health outcomes observed \[[@CIT0041]\]. Our study design did not allow us to discriminate the relative contribution of ART vs close medical monitoring. However, the fact that a similar benefit in clinical outcomes was observed in randomized clinical trials \[[@CIT0012], [@CIT0015]\], where clinical follow-up was standardized between study arms, suggests that our conclusion regarding the benefit of ART at high CD4 cell counts is valid.

Other risk factors for mortality in this study included older age, being male, acquiring HIV through injection drug use or heterosexual transmission, and low educational attainment. In China, HIV incidence has been increasing among older males, particularly in rural areas, who are mainly infected through engaging in commercial sex \[[@CIT0044]\]. Older HIV-infected individuals are more likely to present with comorbidities that increase their risk of death \[[@CIT0045]\]. Mortality was highest among injection drug users, which is related to a variety of factors including delayed ART initiation, poor ART adherence, concomitant drug use, and comorbidities such as depression and hepatitis C virus infection \[[@CIT0046]\].

In contrast to other studies that have examined ART initiation at high CD4 counts \[[@CIT0014]\], an important strength of this study was that all participants who initiated ART in our cohort did so when their CD4 count was \>500 cells/μL. Nevertheless, our study had several limitations. As with any observational study, our data should be interpreted with caution, as participants may have had individual circumstances that could have influenced their treatment initiation decisions, including medical comorbidities. Also, because we used routine care data, we did not have access to some potentially informative variables, such as viral load results, details on complications, and, in some cases, causes of death. Moreover, the delayed ART group and no ART group were subject to a survival bias, as the immediate ART group always included persons who lived long enough to initiate ART. To partially avoid this bias, we treated ART as a time-dependent variable. Finally, as the start of follow-up time was date of CD4 test, and those in the delayed ART group tended to have longer median durations between CD4 testing and ART initiation, the shorter time on ART during follow-up may have contributed to poorer outcomes in this group.

CONCLUSIONS {#s18}
===========

Our results demonstrate that immediate ART initiation within 30 days among PLWH with CD4 counts \>500 cells/μL is associated with a 63% reduction in overall mortality. Our results highlight the significant negative impact of delays in ART initiation in a real-world setting in China. Our findings are consistent with the results of recent randomized controlled trials and demonstrate that these results are generalizable. Furthermore, our results support the urgent need to increase the number of PLWH identified early and started on effective, long-term ART immediately \[[@CIT0013], [@CIT0047]\], as predicated by the United Nations 90-90-90 targets \[[@CIT0038], [@CIT0048], [@CIT0049]\].
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